--- title: "Organon & Co. $OGN Shares Purchased by California State Teachers Retirement System" type: "News" locale: "en" url: "https://longbridge.com/en/news/295626051.md" description: "California State Teachers Retirement System increased its Organon & Co. holdings by 34.8% in Q1, owning 327,075 shares valued at $1.96 million. Other institutions like Royal Bank of Canada and Infrastructure Capital Advisors also raised stakes. Analyst ratings vary from 'Hold' to 'Sell', with a consensus 'Reduce' rating and average price target of $11.40. Organon recently announced a $0.02 quarterly dividend." datetime: "2026-08-12T07:12:57.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295626051.md) - [en](https://longbridge.com/en/news/295626051.md) - [zh-HK](https://longbridge.com/zh-HK/news/295626051.md) generator: "portal-rs" --- # Organon & Co. $OGN Shares Purchased by California State Teachers Retirement System California State Teachers Retirement System lifted its holdings in Organon & Co. (NYSE:OGN - Free Report) by 34.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 327,075 shares of the company's stock after acquiring an additional 84,497 shares during the period. California State Teachers Retirement System owned approximately 0.12% of Organon & Co. worth $1,959,000 as of its most recent SEC filing. - Merck, the Dow's hottest stock, gets set to report Q4 financials Other hedge funds have also made changes to their positions in the company. Royal Bank of Canada grew its stake in shares of Organon & Co. by 8.5% in the first quarter. Royal Bank of Canada now owns 299,663 shares of the company's stock valued at $1,794,000 after buying an additional 23,456 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in Organon & Co. by 8.0% during the 1st quarter. The Manufacturers Life Insurance Company now owns 52,816 shares of the company's stock worth $316,000 after acquiring an additional 3,899 shares in the last quarter. Infrastructure Capital Advisors LLC lifted its position in Organon & Co. by 64.7% during the 1st quarter. Infrastructure Capital Advisors LLC now owns 28,001 shares of the company's stock worth $168,000 after acquiring an additional 11,000 shares in the last quarter. SummitTX Capital L.P. purchased a new position in Organon & Co. in the 1st quarter worth approximately $140,000. Finally, OMERS ADMINISTRATION Corp boosted its holdings in Organon & Co. by 11.1% in the 1st quarter. OMERS ADMINISTRATION Corp now owns 71,334 shares of the company's stock worth $427,000 after acquiring an additional 7,100 shares during the period. Hedge funds and other institutional investors own 77.43% of the company's stock. Get **Organon & Co.** alerts: ## Analysts Set New Price Targets A number of analysts have recently issued reports on the stock. Weiss Ratings lowered shares of Organon & Co. from a "hold (c)" rating to a "hold (c-)" rating in a research note on Monday, August 3rd. Zacks Research upgraded shares of Organon & Co. from a "strong sell" rating to a "hold" rating in a research note on Tuesday, April 14th. Piper Sandler raised shares of Organon & Co. from an "underweight" rating to a "neutral" rating and raised their price target for the company from $5.00 to $14.00 in a report on Tuesday, April 28th. Finally, BNP Paribas Exane reaffirmed a "neutral" rating and set a $14.00 price target (up from $12.00) on shares of Organon & Co. in a research note on Wednesday, April 29th. Five analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Organon & Co. has a consensus rating of "Reduce" and an average price target of $11.40. - Lululemon Athletica Races to New High with S&P 500 Entry **Read Our Latest Stock Report on Organon & Co.** ## Organon & Co. Trading Up 0.3% OGN opened at $13.65 on Wednesday. Organon & Co. has a 12-month low of $5.69 and a 12-month high of $13.66. The company has a debt-to-equity ratio of 8.43, a current ratio of 1.95 and a quick ratio of 1.44. The stock has a market capitalization of $3.59 billion, a PE ratio of 17.73, a P/E/G ratio of 1.26 and a beta of 1.55. The firm's fifty day moving average price is $13.50 and its 200 day moving average price is $10.65. ## Organon & Co. Announces Dividend The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a $0.02 dividend. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Organon & Co.'s dividend payout ratio is 10.39%. ## Organon & Co. Profile (Free Report) Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact. In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies. ## See Also - Five stocks we like better than Organon & Co. - Atlassian Just Pulled Off the Software Comeback Wall Street Wanted - AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be - NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings - Apple’s Next iPhone Could Test How Much Pricing Power Is Left *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in Organon & Co. Right Now? Before you consider Organon & Co., you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organon & Co. wasn't on the list. While Organon & Co. currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [OGN.US](https://longbridge.com/en/quote/OGN.US.md) - [RY.US](https://longbridge.com/en/quote/RY.US.md) - [MRK.US](https://longbridge.com/en/quote/MRK.US.md) - [MFC.US](https://longbridge.com/en/quote/MFC.US.md) - [PIPR.US](https://longbridge.com/en/quote/PIPR.US.md) - [BNPQY.US](https://longbridge.com/en/quote/BNPQY.US.md) - [LULU.US](https://longbridge.com/en/quote/LULU.US.md) - [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md) - [TEAM.US](https://longbridge.com/en/quote/TEAM.US.md) - [ASTS.US](https://longbridge.com/en/quote/ASTS.US.md) - [NVDA.US](https://longbridge.com/en/quote/NVDA.US.md) - [NVD.DE](https://longbridge.com/en/quote/NVD.DE.md) ## Related News & Research - [LGN $LGN Shares Acquired by Royal Bank of Canada](https://longbridge.com/en/news/296590216.md) - [Empowered Funds LLC Sells 315,070 Shares of Zions Bancorporation, N.A. $ZION](https://longbridge.com/en/news/296451424.md) - [OSI Systems (NASDAQ:OSIS) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS](https://longbridge.com/en/news/296532946.md) - [Royal Bank of Canada Increases Holdings in Horace Mann Educators Corporation $HMN](https://longbridge.com/en/news/296326209.md) - [Royal Bank of Canada Acquires 19,619 Shares of Pathward Financial, Inc. $CASH](https://longbridge.com/en/news/296199223.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**